Top

Published in:

Open Access 01-01-2013 | Original Article

The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey

Authors: Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Takashi Terauchi, Tsuyoshi Yoshida, Takeshi Murano, Hiroshi Fukuda, Takeshi Iinuma, Kimiichi Uno, Sadahiko Nishizawa, Eriko Tsukamoto, Hiroshi Iwata, Takeshi Inoue, Kazuhiro Oguchi, Rumi Nakashima, Tomio Inoue

Published in: Annals of Nuclear Medicine | Issue 1/2013

Abstract

Objective

The aim of this study was to survey the 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) cancer screening program conducted in Japan.

Methods

The “FDG-PET cancer screening program” included both FDG-PET and positron emission tomography with computed tomography (PET/CT) with or without other combined screening tests that were performed for cancer screening in asymptomatic subjects. A total of 155,456 subjects who underwent the FDG-PET cancer screening program during 2006–2009 were analyzed.

Results

Of the 155,456 subjects, positive findings suggesting possible cancer were noted in 16,955 (10.9 %). The number of cases with detected cancer was 1,912 (1.23 % of the total screened cases, annual range 1.14–1.30 %). Of the 1,912 cases of detected cancer, positive findings on FDG-PET were present in 1,491 cases (0.96 % of the total number of screened cases). According to the results of further examinations, the true positive rate for subjects with suggested possible cancer (positive predictive value) was 32.3 % with FDG-PET. Cancers of the colon/rectum, thyroid, lung, and breast were most frequently found (396, 353, 319, and 163 cases, respectively) with high PET sensitivity (85.9, 90.7, 86.8, 84.0 %, respectively). Prostate cancer and gastric cancer (165 and 124 cases, respectively) had low PET sensitivity (37.0 and 37.9 %, respectively). The Union for International Cancer Control (UICC) clinical stage of cancer found with the FDG-PET cancer screening program was mainly Stage I.

Conclusions

The FDG-PET screening program in Japan has detected a variety of cancers at an early stage. However, several cancers were found in repeated FDG-PET cancer screening program, indicating the limitation of a one-time FDG-PET cancer screening program. The value of the FDG-PET cancer screening program is left to the judgment of individuals with regard to its potentials and limitations.

Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med. 2007;48(Suppl 1):4S–18S.PubMed

Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging. 2006;50:23–7.PubMed

Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med. 2007;21:481–98.PubMedCrossRef

Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging. 2005;32:342–3.PubMedCrossRef

Ide M, Suzuki Y. Is whole-body FDG-PET valuable for health screening? For. Eur J Nucl Med Mol Imaging. 2005;32:339–41.PubMedCrossRef

Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer. 2000;83:1607–11.PubMedCrossRef

The Foundation for Promotion of Cancer Research (FPCR) Cancer Statistics in Japan 2010 http://ganjoho.jp/public/statistics/backnumber/2010_en.html.

Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med. 2007;21:65–72.PubMedCrossRef

Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body F-18 FDG-PET scans: the Nishidai clinic study. Eur J Cancer. 2007;43:1842–8.PubMedCrossRef

10.

Nishizawa S, Kojima S, Teramukai S, Inubushi M, Kodama H, Maeda Y, et al. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol. 2009;27:1767–73.PubMedCrossRef

11.

Chen YK, Ding HJ, Su CT, Shen YY, Chen LK, Liao AC, et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res. 2004;24:4103–8.PubMed

12.

Ko DH, Choi JY, Song Y, Lee SJ, Kim YH, Lee K, et al. The usefulness of 18F-FDG PET as a cancer screening test. Nucl Med Mol Imaging. 2008;42:444–50.

13.

Lee JW, Kang KW, Paeng JC, Lee SM, Jang SJ, Chung JK, et al. Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. Ann Nucl Med. 2009;23:685–91.PubMedCrossRef

14.

Terauchi T, Murano T, Daisaki H, Kanou D, Shoda H, Kakinuma R, et al. Evaluation of whole-body cancer screening using 18F–2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med. 2008;22:379–85.PubMedCrossRef

15.

Minamimoto R, Senda M, Terauchi T, Jinnouchi S, Inoue T, Iinuma T, et al. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Ann Nucl Med. 2011;25:45–54.PubMedCrossRef

16.

Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35.PubMedCrossRef

17.

Vach W, Flemming P, Hoilund-Carlsen PF, Gerke O, et al. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med. 2011;52:77S–85S.PubMedCrossRef

18.

Murano T, Minamimoto R, Senda M, Uno K, Jinnouchi S, Fukuda H, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Ann Nucl Med. 2011;25:657–66.PubMedCrossRef

19.

Yasunaga H. Who wants cancer screening with PET? A contingent valuation survey in Japan. Eur J Radiol. 2009;70:190–4.PubMedCrossRef

20.

Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:3053–63.PubMedCrossRef

21.

Chen CD, Yen MF, Wang WM, Wong JM, Chen TH. A case-cohort study for the disease natural history of adenomacarcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer. 2003;88:1866–73.PubMedCrossRef

22.

Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. Radiographics. 2007;27:145–59.PubMedCrossRef

23.

Nakajo M, Jinnouchi S, Tashiro Y, Shirahama H, Sato E, Koriyama C, et al. Effect of clinicopathologic factors on visibility of colorectal polyps with FDG PET. AJR Am J Roentgenol. 2009;192:754–60.PubMedCrossRef

Title: The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey
Authors: Ryogo Minamimoto
Michio Senda
Seishi Jinnouchi
Takashi Terauchi
Tsuyoshi Yoshida
Takeshi Murano
Hiroshi Fukuda
Takeshi Iinuma
Kimiichi Uno
Sadahiko Nishizawa
Eriko Tsukamoto
Hiroshi Iwata
Takeshi Inoue
Kazuhiro Oguchi
Rumi Nakashima
Tomio Inoue
Publication date: 01-01-2013
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 1/2013
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-012-0660-x

ACC 2024 Congress

Springer Medicine

The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey

Abstract

Objective

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Predictive value of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma

Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI

Three-dimensional brain phantom containing bone and grey matter structures with a realistic head contour

Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience

Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors

Significant impact of transient deterioration of renal function on dosimetry in PRRT